Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Acerus Pharmaceuticals Corp ASPCQ

Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.


OTCPK:ASPCQ - Post by User

Post by PitchinPennieson Mar 31, 2022 9:46am
158 Views
Post# 34562545

So much for Ian shutting down his "spite store"

So much for Ian shutting down his "spite store"What a class act. Nothing at all to say about the death of the company's founder, but they just put out a news release that Ian is going to dig deeper into his bag of gold-dust to keep his clown car chugging along for a few more months. What would we do without Ian and his ready pile o' cash? Or, more to the point, what will we do with Ian and his obstinate insistance on keeping this zombie company alive from quarter to quarter?

GlobeNewswire

Acerus Pharmaceuticals Corporation (the "Company" or "Acerus") (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. ("First Generation"), a company affiliated with the Chairman of the Board of Directors of Acerus, to increase its existing secured loan facility (the "Loan Facility") from US$30.845 million to US$35.845 million. This increase will be made available to the Company by way of one or more advances under a secured grid promissory note with First Generation provided that any such advance will be made before April 30, 2022.

The Loan Facility bears interest at a rate of eight percent (8%) per annum and is repayable in full on December 31, 2024 but can be prepaid in full or in part without penalty. The proceeds from the Loan Facility will be used for ongoing general working capital.

In light of First Generation's relationship to the Chairman of the Board of Directors of Acerus, the independent members of the Board of Directors, led by the Lead Independent Director, separately met to consider and discuss the amendment to the Loan Facility. Following the review of such independent members of the Board of Directors, it was unanimously determined that the entering into of the amendment to the Loan Facility was in the best interests of Acerus.

 
<< Previous
Bullboard Posts
Next >>